Biomolecular Consequences of Platelet Pathogen Inactivation Methods

Transfusion Medicine Reviews

Volumn 33, Issue 1, 2019, Pages 29-34

  Feys, Hendrik B ^a,b   Van Aelst, Britt ^a   Compernolle, Veerle ^a,b  

^a Rode Kruis Vlaanderen   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Cell damage; Membrane; Metabolism; Pathogen inactivation; Platelets; Signal transduction

Indexed keywords

AMOTOSALEN; NUCLEIC ACID; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; FUROCOUMARIN DERIVATIVE;

ANAEROBIC METABOLISM; DISEASE TRANSMISSION; HEMATOLOGICAL PROCEDURE; HUMAN; METABOLIC RATE; NONHUMAN; PATHOGEN INACTIVATION; PHOTOCHEMISTRY; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE MEMBRANE; TRANSFUSION MEDICINE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; BLOOD BANK; BLOOD STORAGE; BLOOD TRANSFUSION; CHEMISTRY; COMPLICATION; DRUG EFFECT; HEMOSTASIS; MICROBIOLOGY; NEOPLASM; PROCEDURES; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ULTRAVIOLET RADIATION;

BLOOD BANKS; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD TRANSFUSION; FUROCOUMARINS; HEMOSTASIS; HUMANS; NEOPLASMS; NUCLEIC ACIDS; PLATELET TRANSFUSION; RIBOFLAVIN; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; ULTRAVIOLET RAYS;

EID: 85049899142     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2018.06.002     Document Type: Review

References (88)

1. Gowland, P., Fontana, S., Stolz, M., Andina, N., Niederhauser, C., Parvovirus B19 passive transmission by transfusion of Intercept(R) blood system-treated platelet concentrate. Transfus Med Hemother 43 (2016), 198–202.
2. Hauser, L., Roque-Afonso, A.-M., Beylouné, A., Simonet, M., Deau Fischer, B., Burin des Roziers, N., et al. Hepatitis E transmission by transfusion of Intercept blood system–treated plasma. Blood 123 (2014), 796–797.
3. Goodrich, R.P., Gilmour, D., Hovenga, N., Keil, S.D., A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 49 (2009), 1205–1216.
4. Mohr, H., Steil, L., Gravemann, U., Thiele, T., Hammer, E., Greinacher, A., et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 49 (2009), 2612–2624.
5. Marschner, S., Fast, L.D., Baldwin, W.M. III, Slichter, S.J., Goodrich, R.P., White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 50 (2010), 2489–2498.
6. Lin, L., Cook, D.N., Wiesehahn, G.P., Alfonso, R., Behrman, B., Cimino, G.D., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997), 423–435.
7. Wollowitz, S., Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 38 (2001), 4–11.
8. Goodrich, R.P., Edrich, R.A., Li, J., Seghatchian, J., The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 35 (2006), 5–17.
9. Seltsam, A., Muller, T.H., UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 38 (2011), 43–54.
10. Garban, F., Guyard, A., Labussiere, H., Bulabois, C.E., Marchand, T., Mounier, C., et al. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol 4 (2018), 468–475.
11. Ogawa, M., Differentiation and proliferation of hematopoietic stem cells. Blood 81 (1993), 2844–2853.
12. Lefrancais, E., Ortiz-Munoz, G., Caudrillier, A., Mallavia, B., Liu, F., Sayah, D.M., et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 544 (2017), 105–109.
13. Broos, K., Feys, H.B., De Meyer, S.F., Vanhoorelbeke, K., Deckmyn, H., Platelets at work in primary hemostasis. Blood Rev 25 (2011), 155–167.
14. Pleines, I., Lebois, M., Gangatirkar, P., Au, A.E., Lane, R.M., Henley, K.J., et al. Intrinsic apoptosis circumvents the functional decline of circulating platelets, but does not cause the storage lesion. Blood, 2018, 10.1182/blood-2017-11-816355.
15. Shrivastava, M., The platelet storage lesion. Transfus Apher Sci 41 (2009), 105–113.
16. Kaiser-Guignard, J., Canellini, G., Lion, N., Abonnenc, M., Osselaer, J.C., Tissot, J.D., The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 28 (2014), 235–241.
17. Estcourt, L.J., Malouf, R., Hopewell, S., Trivella, M., Doree, C., Stanworth, S.J., et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev, 7, 2017, CD009072.
18. Pelletier, J.P., Transue, S., Snyder, E.L., Pathogen inactivation techniques. Best Pract Res Clin Haematol 19 (2006), 205–242.
19. Wollowitz, S., Targeting DNA and RNA in pathogens: mode of action of Amotosalen HCl. Transfus Med Hemother 31 (2004), 11–16.
20. Lai, C., Cao, H., Hearst, J.E., Corash, L., Luo, H., Wang, Y., Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation. Anal Chem 80 (2008), 8790–8798.
21. Irsch, J., Lin, L., Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 38 (2011), 19–31.
22. Schwertz, H., Koster, S., Kahr, W.H., Michetti, N., Kraemer, B.F., Weitz, D.A., et al. Anucleate platelets generate progeny. Blood 115 (2010), 3801–3809.
23. Bray, P.F., McKenzie, S.E., Edelstein, L.C., Nagalla, S., Delgrosso, K., Ertel, A., et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics, 14(1), 2013.
24. Osman, A., Hitzler, W.E., Ameur, A., Provost, P., Differential expression analysis by RNA-Seq reveals perturbations in the platelet mRNA transcriptome triggered by pathogen reduction systems. PLoS One, 10, 2015, e0133070.
25. Dahiya, N., Sarachana, T., Vu, L., Becker, K.G., Wood, W.H. III, Zhang, Y., et al. Platelet MicroRNAs: an overview. Transfus Med Rev 29 (2015), 215–219.
26. Edelstein, L.C., McKenzie, S.E., Shaw, C., Holinstat, M.A., Kunapuli, S.P., Bray, P.F., MicroRNAs in platelet production and activation. J Thromb Haemost 11:Suppl. 1 (2013), 340–350.
27. Thon, J.N., Devine, D.V., Translation of glycoprotein IIIa in stored blood platelets. Transfusion 47 (2007), 2260–2270.
28. Rowley, J.W., Oler, A.J., Tolley, N.D., Hunter, B.N., Low, E.N., Nix, D.A., et al. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 118 (2011), e101–e111.
29. Denis, M.M., Tolley, N.D., Bunting, M., Schwertz, H., Jiang, H., Lindemann, S., et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122 (2005), 379–391.
30. Landry, P., Plante, I., Ouellet, D.L., Perron, M.P., Rousseau, G., Provost, P., Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 16 (2009), 961–966.
31. Rowley, J.W., Chappaz, S., Corduan, A., Chong, M.M., Campbell, R., Khoury, A., et al. Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets. Blood 127 (2016), 1743–1751.
32. Michael, J.V., Wurtzel, J.G.T., Mao, G.F., Rao, A.K., Kolpakov, M.A., Sabri, A., et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood 130 (2017), 567–580.
33. Osman, A., Hitzler, W.E., Meyer, C.U., Landry, P., Corduan, A., Laffont, B., et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 26 (2015), 154–163.
34. Schoenwaelder, S.M., Darbousset, R., Cranmer, S.L., Ramshaw, H.S., Orive, S.L., Sturgeon, S., et al. 14-3-3zeta regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function. Nat Commun, 7, 2016, 12862.
35. Obydennyy, S.I., Sveshnikova, A.N., Ataullakhanov, F.I., Panteleev, M.A., Dynamics of calcium spiking, mitochondrial collapse and phosphatidylserine exposure in platelet subpopulations during activation. J Thromb Haemost 14 (2016), 1867–1881.
36. Cognasse, F., Aloui, C., Anh Nguyen, K., Hamzeh-Cognasse, H., Fagan, J., Arthaud, C.A., et al. Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers. Transfusion 56 (2016), 497–504.
37. Yasui, K., Matsuyama, N., Kuroishi, A., Tani, Y., Furuta, R.A., Hirayama, F., Mitochondrial damage-associated molecular patterns as potential proinflammatory mediators in post-platelet transfusion adverse effects. Transfusion 56 (2016), 1201–1212.
38. Bruchmuller, I., Losel, R., Bugert, P., Corash, L., Lin, L., Kluter, H., et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 16 (2005), 441–445.
39. Bakkour, S., Chafets, D.M., Wen, L., Dupuis, K., Castro, G., Green, J.M., et al. Assessment of nucleic acid modification induced by amotosalen and ultraviolet a light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion 56 (2016), 410–420.
40. Johnson, L., Loh, Y.S., Kwok, M., Marks, D.C., In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT blood system. Transfus Med 23 (2013), 121–129.
41. Abonnenc, M., Sonego, G., Kaiser-Guignard, J., Crettaz, D., Prudent, M., Tissot, J.D., et al. In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfus 13 (2015), 255–264.
42. Van Aelst, B., Feys, H.B., Devloo, R., Vanhoorelbeke, K., Vandekerckhove, P., Compernolle, V., Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang 108 (2015), 328–339.
43. Stivala, S., Gobbato, S., Infanti, L., Reiner, M.F., Bonetti, N., Meyer, S.C., et al. Amotosalen/ultraviolet a pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica 102 (2017), 1650–1660.
44. Van Aelst, B., Feys, H.B., Devloo, R., Vandekerckhove, P., Compernolle, V., Microfluidic flow chambers using reconstituted blood to model hemostasis and platelet transfusion in vitro. J Vis Exp, 109, 2016, e53823, 10.3791/53823.
45. Van Aelst, B., Devloo, R., Zachee, P., t'Kindt, R., Sandra, K., Vandekerckhove, P., et al. Psoralen and ultraviolet a light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing. J Biol Chem 291 (2016), 24364–24376.
46. Woulfe, D., Jiang, H., Morgans, A., Monks, R., Birnbaum, M., Brass, L.F., Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 113 (2004), 441–450.
47. Chen, X., Zhang, Y., Wang, Y., Li, D., Zhang, L., Wang, K., et al. PDK1 regulates platelet activation and arterial thrombosis. Blood 121 (2013), 3718–3726.
48. Rigg, R.A., Aslan, J.E., Healy, L.D., Wallisch, M., Thierheimer, M.L., Loren, C.P., et al. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function. Am J Physiol Cell Physiol 310 (2016), C373–C380.
49. Dardare, N., Platz, M.S., Binding affinities of commonly employed sensitizers of viral inactivation. Photochem Photobiol 75 (2002), 561–564.
50. Vanni, S., Hirose, H., Barelli, H., Antonny, B., Gautier, R., A sub-nanometre view of how membrane curvature and composition modulate lipid packing and protein recruitment. Nat Commun, 5, 2014, 4916.
51. van Meer, G., Voelker, D.R., Feigenson, G.W., Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol 9 (2008), 112–124.
52. Ciaravino, V., McCullough, T., Dayan, A.D., Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 20 (2001), 533–550.
53. van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilon, D., Ljungman, P., Kluter, H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101 (2003), 2426–2433.
54. Knutson, F., Osselaer, J., Pierelli, L., Lozano, M., Cid, J., Tardivel, R., et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 109 (2015), 343–352.
55. Ruebsaamen, K., Liebisch, G., Boettcher, A., Schmitz, G., Lipidomic analysis of platelet senescence. Transfusion 50 (2010), 1665–1676.
56. Reddy, H.L., Dayan, A.D., Cavagnaro, J., Gad, S., Li, J., Goodrich, R.P., Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 22 (2008), 133–153.
57. Kumar, V., Lockerbie, O., Keil, S.D., Ruane, P.H., Platz, M.S., Martin, C.B., et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 80 (2004), 15–21.
58. Marschner, S., Goodrich, R., Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 38 (2011), 8–18.
59. Zeddies, S., De Cuyper, I.M., van der Meer, P.F., Daal, B.B., de Korte, D., Gutierrez, L., et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 54 (2014), 2292–2300.
60. Feys, H.B., Van Aelst, B., Devreese, K., Devloo, R., Coene, J., Vandekerckhove, P., et al. Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 106 (2014), 307–315.
61. Coene, J., Devreese, K., Sabot, B., Feys, H.B., Vandekerckhove, P., Compernolle, V., Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 54 (2014), 1321–1331.
62. Johnson, L., Marks, D., Treatment of platelet concentrates with the Mirasol pathogen inactivation system modulates platelet oxidative stress and NF-kappaB activation. Transfus Med Hemother 42 (2015), 167–173.
63. Schubert, P., Culibrk, B., Coupland, D., Scammell, K., Gyongyossy-Issa, M., Devine, D.V., Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 52 (2012), 397–408.
64. Schubert, P., Coupland, D., Culibrk, B., Goodrich, R.P., Devine, D.V., Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 53 (2013), 3164–3173.
65. Chen, Z., Schubert, P., Culibrk, B., Devine, D.V., p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment. Transfusion 55 (2015), 848–857.
66. Schubert, P., Culibrk, B., Karwal, S., Serrano, K., Levin, E., Yi, Q., et al. Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality. Transfusion 57 (2017), 2026–2034.
67. Salunkhe, V., De Cuyper, I.M., Papadopoulos, P., van der Meer, P.F., Daal, B.B., Villa-Fajardo, M., et al. A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology. Platelets, 2018, 10.1080/09537104.2018.
68. Cookson, P., Thomas, S., Marschner, S., Goodrich, R., Cardigan, R., In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion 52 (2012), 983–994.
69. Johnson, L., Winter, K.M., Reid, S., Hartkopf-Theis, T., Marschner, S., Goodrich, R.P., et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 101 (2011), 208–214.
70. Picker, S.M., Steisel, A., Gathof, B.S., Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 48 (2008), 1685–1692.
71. Goodrich, R.P., Li, J., Pieters, H., Crookes, R., Roodt, J., Heyns Adu, P., Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 90 (2006), 279–285.
72. Li, J., de Korte, D., Woolum, M.D., Ruane, P.H., Keil, S.D., Lockerbie, O., et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 87 (2004), 82–90.
73. Chen, Z., Schubert, P., Bakkour, S., Culibrk, B., Busch, M.P., Devine, D.V., p38 mitogen-activated protein kinase regulates mitochondrial function and microvesicle release in riboflavin- and ultraviolet light-treated apheresis platelet concentrates. Transfusion 57 (2017), 1199–1207.
74. Dahiya, N., Sarachana, T., Kulkarni, S., Wood, W.H. III, Zhang, Y., Becker, K.G., et al. miR-570 interacts with mitochondrial ATPase subunit g (ATP5L) encoding mRNA in stored platelets. Platelets 28 (2017), 74–81.
75. Drawz, S.M., Marschner, S., Yanez, M., Garcia de Coca, A., Feys, H.B., Deeren, D., et al. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions. Transfusion 55 (2015), 1745–1751.
76. Feys, H.B., Devloo, R., Sabot, B., De Pourcq, K., Coene, J., Compernolle, V., High platelet content can increase storage lesion rates following Intercept pathogen inactivation primarily in platelet concentrates prepared by apheresis. Vox Sang 112 (2017), 751–758.
77. Cadet, J., Sage, E., Douki, T., Ultraviolet radiation-mediated damage to cellular DNA. Mutat Res 571 (2005), 3–17.
78. Thiele, T., Pohler, P., Kohlmann, T., Sumnig, A., Aurich, K., Selleng, K., et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction–a phase I clinical trial. Vox Sang 109 (2015), 44–51.
79. Bashir, S., Cookson, P., Wiltshire, M., Hawkins, L., Sonoda, L., Thomas, S., et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 53 (2013), 990–1000.
80. Johnson, L., Hyland, R., Tan, S., Tolksdorf, F., Sumian, C., Seltsam, A., et al. In vitro quality of platelets with low plasma carryover treated with ultraviolet C light for pathogen inactivation. Transfus Med Hemother 43 (2016), 190–197.
81. Van Aelst, B., Devloo, R., Vandekerckhove, P., Compernolle, V., Feys, H.B., Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro. Transfusion 55 (2015), 2404–2414.
82. de Jager, T.L., Cockrell, A.E., Du Plessis, S.S., Ultraviolet Light Induced Generation of Reactive Oxygen Species. Ahmad, S.I., (eds.) Ultraviolet Light in Human Health, Diseases and Environment, 2017, Springer International Publishing, Cham, 15–23.
83. Zhi, L., Chi, X., Vostal, J.G., In vitro and in vivo characterization of ultraviolet light C-irradiated human platelets in a 2 event mouse model of transfusion. PLoS One, 8, 2013, e79869.
84. Verhaar, R., Dekkers, D.W., De Cuyper, I.M., Ginsberg, M.H., de Korte, D., Verhoeven, A.J., UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 112 (2008), 4935–4939.
85. Sun, Q.H., Liu, C.Y., Wang, R., Paddock, C., Newman, P.J., Disruption of the long-range GPIIIa Cys(5)-Cys(435) disulfide bond results in the production of constitutively active GPIIb-IIIa (alpha(IIb)beta(3)) integrin complexes. Blood 100 (2002), 2094–2101.
86. Butta, N., Arias-Salgado, E.G., Gonzalez-Manchon, C., Ferrer, M., Larrucea, S., Ayuso, M.S., et al. Disruption of the beta3 663-687 disulfide bridge confers constitutive activity to beta3 integrins. Blood 102 (2003), 2491–2497.
87. Kim, K., Hahm, E., Li, J., Holbrook, L.M., Sasikumar, P., Stanley, R.G., et al. Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood 122 (2013), 1052–1061.
88. van der Meer, P.F., Ypma, P.F., van Geloven, N., van Hilten, J.A., van Wordragen-Vlaswinkel, R.J., Eissen, O., et al. Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: a randomized controlled trial. Blood, 2018, 10.1182/blood-2018-02-831289.